SYRE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
81.6M
+7.9%
75.6M
+32.3%
57.2M
+0.5%
56.9M
+9.5%
51.9M
R&D
65.5M
+8.4%
60.4M
+35.3%
44.6M
-1.3%
45.2M
+12.7%
40.1M
SG&A
16.1M
+5.9%
15.2M
+21.5%
12.5M
+7.7%
11.6M
-1.3%
11.8M
Operating Income
-81639000
-7.9%
-75641000
-32.3%
-57172000
-0.5%
-56888000
-9.5%
-51935000
EBITDA
-81639000
-7.9%
-75641000
-32.3%
-57172000
-0.5%
-56888000
-9.5%
-51935000
Net Income
-36200000
+47.5%
-69005000
-10.4%
-62530000
-459.2%
-11183000
+69.5%
-36717000
EPS (Basic)
$-0.36
+51.4%
$-0.74
-7.2%
$-0.69
-360.0%
$-0.15
+69.4%
$-0.49
EPS (Diluted)
$-0.36
+51.4%
$-0.74
-7.2%
$-0.69
-360.0%
$-0.15
+69.4%
$-0.49
Shares (Diluted)
84.7M
+7.9%
78.5M
+4.4%
75.2M
+24.5%
60.4M
+0.1%
60.3M
Spyre Therapeutics (SYRE) โ€” Financials